Blueprint Medicines Co. (NASDAQ:BPMC - Get Free Report) COO Christina Rossi sold 2,274 shares of Blueprint Medicines stock in a transaction dated Wednesday, December 18th. The shares were sold at an average price of $95.91, for a total value of $218,099.34. Following the completion of the transaction, the chief operating officer now owns 69,383 shares in the company, valued at $6,654,523.53. This trade represents a 3.17 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
Christina Rossi also recently made the following trade(s):
- On Wednesday, November 27th, Christina Rossi sold 2,274 shares of Blueprint Medicines stock. The shares were sold at an average price of $95.10, for a total transaction of $216,257.40.
Blueprint Medicines Price Performance
Blueprint Medicines stock opened at $90.14 on Friday. The company has a debt-to-equity ratio of 1.09, a quick ratio of 3.27 and a current ratio of 3.32. The company's fifty day moving average price is $92.45 and its 200 day moving average price is $97.23. The stock has a market capitalization of $5.73 billion, a P/E ratio of -42.72 and a beta of 0.59. Blueprint Medicines Co. has a 1 year low of $72.24 and a 1 year high of $121.90.
Is Starlink Set For The Largest IPO In History?
From Paradigm Press | Ad
He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant.
Then, he did it again with Tesla… which is up more than 19,500% since 2010.
For perspective, that turns $100 invested into almost $20,000!
Click here now for the urgent details.
Blueprint Medicines (NASDAQ:BPMC - Get Free Report) last released its quarterly earnings results on Wednesday, October 30th. The biotechnology company reported ($0.89) earnings per share for the quarter, topping the consensus estimate of ($0.97) by $0.08. Blueprint Medicines had a negative net margin of 29.48% and a negative return on equity of 112.30%. The firm had revenue of $128.20 million during the quarter, compared to the consensus estimate of $127.56 million. During the same quarter in the prior year, the firm earned ($2.20) EPS. The company's revenue for the quarter was up 126.5% on a year-over-year basis. As a group, equities research analysts anticipate that Blueprint Medicines Co. will post -3.68 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
Several equities research analysts have weighed in on BPMC shares. HC Wainwright restated a "buy" rating and issued a $135.00 target price on shares of Blueprint Medicines in a research note on Friday, November 15th. Wedbush reaffirmed an "outperform" rating and set a $135.00 target price on shares of Blueprint Medicines in a research report on Thursday, November 14th. JPMorgan Chase & Co. started coverage on Blueprint Medicines in a research note on Thursday, November 14th. They issued an "overweight" rating and a $126.00 price target for the company. StockNews.com upgraded Blueprint Medicines from a "sell" rating to a "hold" rating in a research note on Friday, November 8th. Finally, JMP Securities reiterated a "market outperform" rating and issued a $125.00 target price on shares of Blueprint Medicines in a research note on Monday, December 9th. One research analyst has rated the stock with a sell rating, seven have given a hold rating, twelve have assigned a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, Blueprint Medicines has an average rating of "Moderate Buy" and an average target price of $122.11.
Get Our Latest Research Report on BPMC
Institutional Investors Weigh In On Blueprint Medicines
Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Quarry LP purchased a new position in shares of Blueprint Medicines during the 3rd quarter worth $32,000. Covestor Ltd grew its stake in shares of Blueprint Medicines by 206.7% in the third quarter. Covestor Ltd now owns 598 shares of the biotechnology company's stock valued at $55,000 after buying an additional 403 shares in the last quarter. Van ECK Associates Corp raised its holdings in shares of Blueprint Medicines by 13.3% in the 2nd quarter. Van ECK Associates Corp now owns 1,116 shares of the biotechnology company's stock valued at $120,000 after buying an additional 131 shares during the period. Quantbot Technologies LP acquired a new position in Blueprint Medicines during the 3rd quarter worth about $108,000. Finally, Values First Advisors Inc. acquired a new position in Blueprint Medicines in the 3rd quarter valued at about $122,000.
About Blueprint Medicines
(
Get Free Report)
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
